Centene Corp Reports Director Departure and Shareholder Votes

Centene Corp (NYSE: CNC) reported the departure of a director and detailed voting outcomes from its annual shareholder meeting in a Form 8-K submitted to the Securities and Exchange Commission on May 15, 2026.

The filing covers two items required under SEC rules. Item 5.02 addresses the departure or election of directors or principal officers. Item 5.07 addresses the submission of matters to a vote of security holders. Centene, which provides managed health care services primarily to government-sponsored programs including Medicaid, serves more than 28 million members nationwide as of its most recent public disclosures.

The 8-K states that one director has departed the board. The filing does not name the individual, specify the exact effective date beyond the filing itself, or cite a cause for the departure. Under SEC rules, a company must amend its disclosures within four business days of a triggering event involving a director's resignation or removal.

This departure shifts board composition and requires Centene to update its governance documents and committee assignments in subsequent filings such as its next proxy statement or Form 10-K.

The shareholder vote results under Item 5.07 establish the official tally for director elections, say-on-pay proposals, and any other matters presented. These certified outcomes now fix the membership of the board for the coming year and ratify compensation and auditor decisions.

The vote tallies trigger Centene's obligation to report final results in this 8-K and to reflect them in its ongoing SEC reporting. Downstream, the board must now act on any approved compensation policies within the timelines set by its compensation committee charter, while the company prepares updated governance disclosures for its 2027 proxy.

Standard contractual covenants in Centene's debt agreements and insurance licenses often reference board stability and require notification to counterparties or regulators when composition changes exceed defined thresholds.

This 8-K represents the company's required disclosure following its 2026 annual meeting. The filing follows the standard schedule for public companies after shareholder meetings and contains no indication of related litigation or regulatory inquiries. Centene must incorporate the board change into its next quarterly report or proxy materials as required by SEC Regulation S-K.